Tempus AI (TEM.US), a leading technology company dedicated to advancing artificial intelligence in precision medicine, has released preliminary unaudited financial highlights for the fourth quarter and full year ending December 31, 2025. The report indicates that its full-year 2025 revenue is approximately $1.27 billion, representing a year-over-year increase of about 83% (including approximately 30% organic growth, excluding contributions from the Ambry Genetics business). At the time of writing, the stock was up 12% in pre-market trading.
Data shows that the company's 2025 diagnostic business revenue reached approximately $955 million, a surge of about 111% compared to the prior year, primarily driven by a roughly 26% increase in oncology testing volume and a 29% rise in genetic testing volume. Revenue from the Data & Applications business hit $316 million, growing about 31% year-over-year, largely fueled by a 38% expansion in the Insights business.
Furthermore, Tempus AI announced that as of December 31, 2025, its total contract value has surpassed $1.1 billion, setting a new historical record. The company's fourth-quarter 2025 data reveals revenue of approximately $367 million, an increase of about 83% year-over-year.
Diagnostic business revenue for the fourth quarter was about $266 million, soaring 121% compared to the same period last year, mainly propelled by a 29% growth in oncology testing volume and a 23% increase in genetic testing volume. Data & Applications business revenue was approximately $100 million, up 25% year-over-year (when adjusting for the impact of an AstraZeneca warrant in Q4 2024, the Insights business grew about 68%).
Eric Lefkofsky, Founder and CEO of Tempus, stated, "2025 was an exceptional year for Tempus, with performance across both of our product lines exceeding our initial expectations for the year. Within our diagnostic business, volume growth for our genomics (oncology) product has accelerated for three consecutive quarters, reaching the highest unit growth rate in years. Our Data & Applications business performed even more strongly, achieving a record of approximately $100 million in revenue in the fourth quarter and growing about 31% for the full year, with data licensing up about 38%. We enter 2026 with exceptional momentum, growth accelerating across both core businesses, and the inherent financial leverage of our platform being realized. With AI acting as a catalyst across all of our offerings, we are excited for 2026."
Tempus has not yet completed the preparation of its financial statements for the fourth quarter and full year 2025. The fourth-quarter and full-year data for the period ended December 31, 2025, disclosed here are preliminary, unaudited, and subject to inherent uncertainties, and therefore may be adjusted as Tempus finalizes its financial results for the period.
Comments